{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:30:33Z","timestamp":1791639033837,"version":"4.3.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":3016,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinicians alter dosing for desoxycorticosterone pivalate (DOCP) to mitigate costs, but this practice has not been critically evaluated in a prospective clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>The duration of action of DOCP is longer than 30\u00a0days in dogs with primary hypoadrenocorticism (PH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>A total of 53 client-owned dogs with PH. Twenty-four dogs with newly diagnosed PH (Group 1) and 29 dogs with treated PH (Group 2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, multicenter, clinical trial. For phase I, DOCP was administered and plasma sodium and potassium concentrations were measured until the dog developed hyponatremia or hyperkalemia at a planned evaluation, or displayed clinical signs with plasma electrolyte concentrations outside of the reference interval independent of a planned evaluation, thus defining DOCP duration of action. Plasma electrolyte concentrations then were assessed at the end of the individualized dosing interval (IDI; i.e., DOCP duration of action minus 7\u00a0days, phase II and at least 3\u00a0months after concluding phase II, phase III).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The duration of action of DOCP in dogs in phase I with na\u00efve PH (n\u00a0=\u00a024) ranged from 32 to 94\u00a0days (median, 62\u00a0days; 95% confidence interval [CI], 57, 65) and previously treated PH (n\u00a0=\u00a029) from 41 to 124\u00a0days (median, 67\u00a0days; CI, 56, 72). Overall, the final DOCP dosing interval for all dogs that completed phase II (n\u00a0=\u00a036) ranged from 38\u00a0days to 90\u00a0days (median, 58\u00a0days; CI, 53, 61). No dog that completed phase III (n\u00a0=\u00a015) required reduction in the IDI. The DOCP duration of action, independent of group, was not significantly associated with several baseline variables. The median drug cost reduction using IDI was approximately 57.5% per year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Clinical Importance<\/jats:title>\n                    <jats:p>The duration of action of DOCP in dogs with PH is &amp;gt;30\u00a0days, and plasma sodium and potassium concentrations can be maintained with an IDI &amp;gt;30\u00a0days long term.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.14828","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T11:20:17Z","timestamp":1505128817000},"page":"1649-1657","source":"Crossref","is-referenced-by-count":22,"title":["Desoxycorticosterone Pivalate Duration of Action and Individualized Dosing Intervals in Dogs with Primary Hypoadrenocorticism"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0270-4728","authenticated-orcid":false,"given":"J.A.","family":"Jaffey","sequence":"first","affiliation":[{"name":"East Bay Veterinary Specialists Department of Internal Medicine, , Walnut Creek, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Nurre","sequence":"additional","affiliation":[{"name":"East Bay Veterinary Specialists Department of Internal Medicine, , Walnut Creek, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Cannon","sequence":"additional","affiliation":[{"name":"Lauderdale Veterinary Specialists Department of Internal Medicine, , Ft. Lauderdale, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.E.","family":"DeClue","sequence":"additional","affiliation":[{"name":"Veterinary Health Center, University of Missouri Department of Veterinary Medicine and Surgery, , Columbia, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"key":"2026020303230423100_jvim14828-bib-0001","first-page":"485","article-title":"Canine and Feline Endocrinology","author":"Scott-Moncrieff","year":"2015","edition":"4"},{"key":"2026020303230423100_jvim14828-bib-0002","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.tcam.2014.10.001","article-title":"Canine hypoadrenocorticism: Pathogenesis, diagnosis, and treatment","volume":"29","author":"Van Lanen","year":"2014","journal-title":"Top Companion Anim Med"},{"key":"2026020303230423100_jvim14828-bib-0003","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1939-1676.1997.tb00072.x","article-title":"Treatment and long-term follow-up of 205 dogs with hypoadrenocorticism","volume":"11","author":"Kintzer","year":"1997","journal-title":"J Vet Intern Med"},{"key":"2026020303230423100_jvim14828-bib-0004","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/jvim.12581","article-title":"Incidence, severity and prognosis associated with hyponatremia in dogs and cats","volume":"29","author":"Ueda","year":"2015","journal-title":"J Vet Intern Med"},{"key":"2026020303230423100_jvim14828-bib-0005","first-page":"269","article-title":"Small Animal Critical Care Medicine","author":"Riordan","year":"2015","edition":"2"},{"key":"2026020303230423100_jvim14828-bib-0006","first-page":"517","article-title":"Small Animal Clinical Pharmacology","author":"Church","year":"2008","edition":"2"},{"key":"2026020303230423100_jvim14828-bib-0007","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2460\/javma.1993.202.03.392","article-title":"Efficacy of microcrystalline desoxycorticosterone pivalate for treatment of hypoadrenocorticism in dogs","volume":"202","author":"Lynn","year":"1993","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303230423100_jvim14828-bib-0008","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/0007-1935(91)90091-Z","article-title":"Treatment of canine hypoadrenocorticism with microcrystalline desoxycorticosterone pivalate","volume":"147","author":"Lynn","year":"1991","journal-title":"Br Vet J"},{"key":"2026020303230423100_jvim14828-bib-0009","first-page":"248","article-title":"Diagnostic value of plasma aldosterone\/potassium ratio in hypoaldosteronism","volume":"94","author":"Shiah","year":"1995","journal-title":"J Formos Med Assoc"},{"key":"2026020303230423100_jvim14828-bib-0010","first-page":"259","article-title":"Diagnosis and therapy surveillance in Addison's disease: Rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone","volume":"75","author":"Oelkers","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2026020303230423100_jvim14828-bib-0011","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/jvim.12243","article-title":"Evaluation of aldosterone concentrations in dogs with hypoadrenocorticism","volume":"28","author":"Baumstark","year":"2014","journal-title":"J Vet Intern Med"},{"key":"2026020303230423100_jvim14828-bib-0012","first-page":"92","article-title":"Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice","author":"Dibartola","year":"2012","edition":"4"},{"key":"2026020303230423100_jvim14828-bib-0013","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1084\/jem.61.6.839","article-title":"Studies on the Suprarenal Cortex. IV. The effect of sodium salts in sustaining the suprarenalectomized dog","volume":"61","author":"Harrop","year":"1935","journal-title":"J Exp Med"},{"key":"2026020303230423100_jvim14828-bib-0014","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.beem.2014.08.008","article-title":"Mineralocorticoid substitution and monitoring in primary adrenal insufficiency","volume":"29","author":"Quinkler","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026020303230423100_jvim14828-bib-0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF01469025","article-title":"Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement","volume":"54","author":"Oelkers","year":"1976","journal-title":"Klin Wochenschr"},{"key":"2026020303230423100_jvim14828-bib-0016","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2265.1996.00838.x","article-title":"The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency","volume":"45","author":"Flad","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026020303230423100_jvim14828-bib-0017","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/jvim.12426","article-title":"Use of plasma renin activity to monitor mineralocorticoid treatment in dogs with primary hypoadrenocorticism: Desoxycorticosterone versus fludrocortisone","volume":"28","author":"Baumstark","year":"2014","journal-title":"J Vet Intern Med"},{"key":"2026020303230423100_jvim14828-bib-0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0140-6736(84)90181-8","article-title":"Evidence that patients with Addison's Disease are undertreated with fludrocortisone","volume":"323","author":"Smith","year":"1984","journal-title":"Lancet"},{"key":"2026020303230423100_jvim14828-bib-0019","first-page":"179","article-title":"Canine hypoadrenocorticism: Part II","volume":"51","author":"Klein","year":"2010","journal-title":"Can Vet J"},{"key":"2026020303230423100_jvim14828-bib-0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1476-4431.2001.tb00058.x","article-title":"The treatment of acute adrenocortical insufficiency in the dog","volume":"11","author":"Schaer","year":"2001","journal-title":"J Vet Emerg Crit Care"},{"key":"2026020303230423100_jvim14828-bib-0021","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00000441-200403000-00007","article-title":"Life-threatening hypokalemia in an asthmatic patient treated with high dose hydrocortisone","volume":"327","author":"Tsai","year":"2004","journal-title":"Am J Med Sci"},{"key":"2026020303230423100_jvim14828-bib-0022","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0006-2952(02)01074-2","article-title":"Predicting plasma protein binding of drugs: A new approach","volume":"64","author":"Kratochwil","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"2026020303230423100_jvim14828-bib-0023","article-title":"Desoxycorticosterone pivalate"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.14828","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/31\/6\/1649\/66667667\/jvim14828.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/31\/6\/1649\/66667667\/jvim14828.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:23:12Z","timestamp":1770106992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/31\/6\/1649\/8449226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.14828","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11]]},"published":{"date-parts":[[2017,11,1]]}}}